In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality

Mark H. Ebell

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)410
Number of pages1
JournalAmerican Family Physician
Volume93
Issue number5
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Cause of Death
Cardiovascular Diseases
Mortality
empagliflozin
Global Health

ASJC Scopus subject areas

  • Family Practice

Cite this

In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality. / Ebell, Mark H.

In: American Family Physician, Vol. 93, No. 5, 01.03.2016, p. 410.

Research output: Contribution to journalArticle

@article{4b01c0f43392411a9885e90980456349,
title = "In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality",
author = "Ebell, {Mark H.}",
year = "2016",
month = "3",
day = "1",
language = "English (US)",
volume = "93",
pages = "410",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "5",

}

TY - JOUR

T1 - In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality

AU - Ebell, Mark H.

PY - 2016/3/1

Y1 - 2016/3/1

UR - http://www.scopus.com/inward/record.url?scp=84959449270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959449270&partnerID=8YFLogxK

M3 - Article

C2 - 26926979

AN - SCOPUS:84959449270

VL - 93

SP - 410

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 5

ER -